source
- Novartis' Lutathera radioligand therapy may soon face first generic challengerNovartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product. A rival company is preparing to launch the first generic version, which could introd…
- Sanofi’s research focus may shift under new CEO Belén Garijo, amid gene therapy advances and telehealth debatesSanofi is entering a period of strategic reassessment as Belén Garijo assumes the chief executive role. Observers are watching to see whether the company will adjust its recent emphasis on immunolo…